BioXcel Therapeutics
BioXcel Therapeutics develops transformative medicines in neuroscience and immuno-oncology using AI techniques, with notable products like IGALMI™ and BXCL501.
Introduction to BioXcel Therapeutics
BioXcel Therapeutics focuses on the development of transformative medicines in the fields of neuroscience and immuno-oncology. The company employs an artificial intelligence (AI) platform to reduce therapeutic development costs, potentially accelerate timelines, and increase the possibility of success. BioXcel Therapeutics' headquarters is located at 555 Long Wharf Drive, 12th Floor, New Haven, CT 06511, United States.
BioXcel Therapeutics AI Platform
BioXcel Therapeutics utilizes a unique AI platform called NovareAI to streamline the discovery and development of new indications for existing late-stage drug candidates and approved drugs. This approach aims to expedite the drug development process and maximize the efficacy and safety profiles of new therapeutic candidates. The proactive use of AI at BioXcel has led to significant advancements, including the rapid acceleration of their first commercial product, IGALMI™ (dexmedetomidine) sublingual film, from clinical trials to FDA approval and launch in under four years.
FDA-Approved Products
BioXcel Therapeutics has received FDA approval for IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. This transformative product underscores the company's capabilities in bringing AI-driven medicines to market efficiently and effectively.
Clinical-Stage Subsidiary: OnkosXcel Therapeutics
BioXcel Therapeutics operates a wholly owned subsidiary, OnkosXcel Therapeutics, which primarily focuses on developing therapeutics in immuno-oncology. Formed in 2022, OnkosXcel aims to advance new treatment options for patients with hard-to-treat tumors. One of its investigational drugs, BXCL701, is an oral innate immune activator being developed for aggressive prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Investigational Products
BioXcel Therapeutics is evaluating BXCL501, a potential treatment for agitation associated with multiple psychiatric and neurological disorders. The FDA has granted Breakthrough Therapy designation for the acute treatment of agitation associated with dementia and Fast Track designation for schizophrenia, bipolar disorders, and dementia. Additionally, BXCL701 is being investigated for aggressive forms of cancer, including prostate and pancreatic cancers, among others, and has received Orphan Drug Designation in four indications and Fast Track designation for small cell neuroendocrine phenotype (SCNC).